Document Detail

Involvement of dorsal raphe nucleus and dorsal periaqueductal gray 5-HT receptors in the modulation of mouse defensive behaviors.
MedLine Citation:
PMID:  20570114     Owner:  NLM     Status:  MEDLINE    
Previous findings point to the involvement of the dorsal raphe nucleus (DRN) and dorsal periaqueductal gray (dPAG) serotonergic receptors in the mediation of defensive responses that are associated with specific subtypes of anxiety disorders. These studies have mostly been conducted with rats tested in the elevated T-maze, an experimental model of anxiety that was developed to allow the measurement, in the same animal, of two behaviors mentioned: inhibitory avoidance and one-way escape. Such behavioral responses have been respectively related to generalized anxiety disorder (GAD) and panic disorder (PD). In order to assess the generality of these findings, in the current study we investigated the effects of the injection of 5-HT-related drugs into the DRN and dPAG of another rodent species, mouse, on the mouse defense test battery (MDTB), a test of a range of defensive behaviors to an unconditioned threat, a predator. Male CD-1 mice were tested in the MDTB after intra-DRN administration of the 5-HT(1A) receptor antagonist WAY-100635 or after intra-dPAG injection of two serotonergic agonists, the 5-HT(1A) receptor agonist 8-OH-DPAT and the 5-HT(2A/2C) receptor agonist DOI. Intra-DRN injection of WAY-100635 did not change behavioral responses of mice confronted with a rat in the MDTB. In the dPAG, both 8-OH-DPAT and DOI consistently impaired mouse escape behavior assessed in the MDTB. Intra-dPAG infusion of 8-OH-DPAT also decreased measures of mouse risk assessment in the rat exposure test. In conclusion, the current findings are in partial agreement with previous results obtained with rats tested in the elevated T-maze. Although there is a high level of similarity between the behavioral effects obtained in rats (elevated T-maze) and mice (MDTB and RET) with the infusion of 5-HT agonists into the dPAG, the same is not true regarding the effects of blockade of DRN 5-HT(1A) receptors in these rodent species. These data suggest that there may be differences between mice and rats regarding the involvement of the DRN in the mediation of defensive behaviors.
Roger L H Pobbe; Helio Zangrossi; D Caroline Blanchard; Robert J Blanchard
Related Documents :
11224054 - Dual activation by lisuride of central serotonin 5-ht(1a) and dopamine d(2) receptor si...
20872754 - 5-ht₁a receptor binding is increased after recovery from bulimia nervosa compared to ...
12916054 - Synthesis of heteroarylpiperazines and heteroarylbipiperidines with a restricted side c...
10607554 - Ringing changes to the 'bell-shaped curve'.
3013234 - The periaqueductal gray: a prerequisite for acth-induced excessive grooming.
11390464 - The p2y11 receptor mediates the atp-induced maturation of human monocyte-derived dendri...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-05-31
Journal Detail:
Title:  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology     Volume:  21     ISSN:  1873-7862     ISO Abbreviation:  Eur Neuropsychopharmacol     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-11     Completed Date:  2011-06-15     Revised Date:  2014-09-20    
Medline Journal Info:
Nlm Unique ID:  9111390     Medline TA:  Eur Neuropsychopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  306-15     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier B.V. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anxiety Disorders / metabolism
Behavior, Animal / drug effects*
Escape Reaction / drug effects
Immobility Response, Tonic / drug effects
Infusions, Intraventricular
Nerve Tissue Proteins / agonists,  antagonists & inhibitors,  physiology
Neurons / drug effects
Panic Disorder / metabolism
Periaqueductal Gray / drug effects*
Raphe Nuclei / drug effects*
Receptor, Serotonin, 5-HT1A / physiology
Receptor, Serotonin, 5-HT2A / physiology
Receptor, Serotonin, 5-HT2C / physiology
Receptors, Serotonin / physiology*
Serotonin 5-HT1 Receptor Agonists / administration & dosage,  pharmacology
Serotonin 5-HT1 Receptor Antagonists / administration & dosage,  pharmacology
Serotonin 5-HT2 Receptor Agonists / administration & dosage,  pharmacology
Species Specificity
Grant Support
R01 MH081845/MH/NIMH NIH HHS; U54 NS039406-06/NS/NINDS NIH HHS
Reg. No./Substance:
0/Nerve Tissue Proteins; 0/Receptor, Serotonin, 5-HT2A; 0/Receptor, Serotonin, 5-HT2C; 0/Receptors, Serotonin; 0/Serotonin 5-HT1 Receptor Agonists; 0/Serotonin 5-HT1 Receptor Antagonists; 0/Serotonin 5-HT2 Receptor Agonists; 112692-38-3/Receptor, Serotonin, 5-HT1A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
Next Document:  Childhood methylphenidate treatment of ADHD and response to affective stimuli.